

GLAXOSMITHKLINE PLC
 Form 6-K
 February 21, 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

 - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£0.0000	67,867 (Deferred)
£0.0000	22,621 (Matching)

- Aggregated information
- d) Aggregated volume Price 90,448
£0.0000
 - e) Date of the transaction 2017-02-20
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer

- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-------------------|
| £16.3353 | 31,898 (Deferred) |
| £16.3353 | 10,633 (Matching) |

- Aggregated information
- d) Aggregated volume Price 42,531
£16.3353
- e) Date of the transaction 2017-02-20
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms E Walmsley
- b) Position/status CEO Designate
- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
c) Price(s) and volume(s)	Price(s) Volume(s) £0.0000 14,860 (Deferred) £0.0000 4,954 (Matching)
d) Aggregated information	
d) Aggregated volume Price	19,814 £0.0000
e) Date of the transaction	2017-02-21
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status CEO Designate
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 - a) Description of the financial instrument

- b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred

Annual Bonus Plan – Deferred
 Bonus and Matching Awards.

Price(s) Volume(s)
 £16.3500 6,986 (Deferred)
 £16.3500 2,330 (Matching)

c) Price(s) and volume(s)

Aggregated information

d) Aggregated volume Price 9,316
 £16.3500
 e) Date of the transaction 2017-02-21
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction The exercise of nil-cost
 options over Ordinary Shares
 granted on 12 February 2014
 under the Company's 2009
 Deferred Annual Bonus Plan –
 Deferred Bonus and Matching
 Awards.

c) Price(s) and volume(s) Price(s) Volume(s)
 £0.0000 12,115 (Deferred)
 £0.0000 4,039 (Matching)

Aggregated information

d) Aggregated volume Price 16,154
 £0.0000
 e) Date of the transaction 2017-02-20
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.3425	5,809 (Deferred)
£16.3450	1,937 (Matching)
 - d) Aggregated information

Aggregated volume	7,746
Price	£16.3431
 - e) Date of the transaction 2017-02-20
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, Human Resources
 - c) Initial notification/ amendment Initial Notification
- 2.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------|
| £0.0000 | 7,517 (Deferred) |
| £0.0000 | 2,506 (Matching) |

Aggregated information

- d) Aggregated volume Price 10,023
£0.0000
- e) Date of the transaction 2017-02-20
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
 b) Position/status SVP, Human Resources
 c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.3700 3,604 (Deferred) £16.3550 1,202 (Matching)
d) Aggregated information	
d) Aggregated volume Price	4,806 £16.3662
e) Date of the transaction	2017-02-20
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status SVP, Communications & Government Affairs
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

 - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and

Matching Awards.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£0.0000	4,528 (Deferred)
	£0.0000	1,509 (Matching)

Aggregated information

d) Aggregated volume Price	6,037
	£0.0000
e) Date of the transaction	2017-02-20
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr P C Thomson
b) Position/status	SVP, Communications & Government Affairs
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--------------------------------------------	--------------------

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.3450	2,171 (Deferred)
	£16.3500	724 (Matching)

Aggregated information

d) Aggregated volume Price	2,895
	£16.3462

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2017-02-20
- f) Place of the transaction London Stock Exchange
(XLON)